In pSS patients, plasma PCSK9 levels did not correlate with hsCRP (r = 0.043, p = 0.861), even when accounting for the potential confounding effect of ongoing therapy with either corticosteroids/immunomodulators (r = 0.035, p = 0.889) or statins (r = 0.104, p = 0.682). Here, PCSK9 is linked to peeling skin syndrome.